Perceptive steers LianBio's globally connected China strategy to $325M IPO
LianBio was founded to tackle a big mission: to take the in-licensing strategy that’s been popularized in China over the past decade and supercharge it with rich global connections and a creative approach to dealmaking.
Now, the high-profile Perceptive startup has bagged $325 million to go even bigger as a public company.
The biotech has priced its IPO at $16 a share — for more than 20 million shares — giving it a fully diluted value of about $1.88 billion, according to Bloomberg.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
